Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Status:
Completed
Trial end date:
2019-03-08
Target enrollment:
Participant gender:
Summary
This open-label, non-randomized trial will comprise of 2 parts. A dose escalation part will
characterize the safety, biomarker and pharmacokinetics of OPB-111077 in advanced solid
tumor. Subsequently, an expansion part will further evaluate the biomarker, safety,
pharmacokinetics and antitumor activity of OPB-111077 in selected tumor types.